Razelle Kurzrock
Affiliations: | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Molecular Biology, Cell Biology, Genetics, OncologyGoogle:
"Razelle Kurzrock"Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Louie BH, Kato S, Kim KH, et al. (2022) Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. Npj Precision Oncology. 6: 67 |
| Tsimberidou AM, Fountzilas E, Bleris L, et al. (2020) Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Seminars in Cancer Biology |
| Bohan SS, Sicklick JK, Kato SM, et al. (2020) Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. The Oncologist |
| Nikanjam M, Riviere P, Goodman A, et al. (2020) Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 9: 1781997 |
| Zhang T, Pabla S, Lenzo FL, et al. (2020) Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncoimmunology. 9: 1773200 |
| Charo LM, Eskander RN, Okamura R, et al. (2020) Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Molecular Oncology |
| Louie BH, Kurzrock R. (2020) BAP1: Not just a BRCA1-associated protein. Cancer Treatment Reviews. 90: 102091 |
| Adashek JJ, Arroyo-Martinez Y, Menta AK, et al. (2020) Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Frontiers in Oncology. 10: 1312 |
| Kurzrock R. (2020) Selpercatinib Aimed at -Altered Cancers. The New England Journal of Medicine. 383: 868-869 |
| Agashe R, Kurzrock R. (2020) Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers. 12 |